| Autor: |
Merrick, VM, Mortier, K, Williams, LJ, Muhammed, R, Auth, MK, Elawad, M, Fell, JM, Beattie, RM, Loganathan, S, Torrente, F, Morris, M-A, Charlton, C, Croft, NM, Rodrigues, A, Furman, M, Vadamalayan, B, Jenkins, H, Zamvar, V, Mitton, SG, Chong, S, Cosgrove, M, Akobeng, A, Wilson, DC, Russell, RK |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| ISSN: |
1536-4801 |
| Popis: |
OBJECTIVES: To measure the effectiveness, safety and use of anti-Tumour necrosis Factor (TNF) therapy in paediatric inflammatory bowel disease (PIBD) in the United Kingdom (UK). METHODS: Prospective UK audit of patients newly starting anti-TNF therapy. Disease severity was assessed using Physician Global Assessment (PGA) +/or the Paediatric Crohn's Disease Activity Index (PCDAI). RESULTS: 37 centres participated (23 of 25 specialist PIBD sites). 524 patients were included; 429 Crohn's disease (CD), 76 ulcerative colitis (UC), 19 IBD unclassified (IBDU). 87% (488/562) anti-TNF was infliximab; commonest indication was active luminal CD 77% (330/429) or chronic refractory UC/IBDU 56% (53/95); 79% (445/562) had concomitant co-immunosuppression. In CD (267/429 male), median time from diagnosis to treatment was 1.42 years (IQR 0.63-2.97). Disease (at initiation) was moderate or severe in 91% (156/171) by PGA compared to 41% (88/217) by PCDAI; Kappa (Κ) 0.28 = only 'fair agreement' (p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text